General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Epkinly (concluded with pTAP LOI) (epcoritamab)
Status:
Concluded with an LOI
Manufacturer:
AbbVie Corporation
Indication:
Diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) Relapsed or refractory , DLBCL transformed from indolent lymphoma, high grade B-cell lymphoma (HGBCL), primary mediastinal B-cell lymphoma (PMBCL) or follicular lymphoma Grade 3B (FLG3b), in adult patients, after two or more lines of systemic therapy and who have previously received or are unable to receive CAR-T cell therapy.
Last updated July 19, 2024
Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
Renal Cell Carcinoma (RCC), advanced (not amenable to curative surgery or radiation therapy) or metastatic, first-line treatment of adult patients (in combination with nivolumab)
Last updated July 17, 2024
Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
Stage IIB or IIC melanoma following complete resection, monotherapy for the adjuvant treatment of adult patients
Last updated July 17, 2024
Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
Psoriasis, moderate to severe plaque
Last updated July 17, 2024
TheraSphere Y-90 Glass Micropheres (Yttrium-90 microspheres)
Status:
Concluded without agreement
Manufacturer:
Boston Scientific Corporation
Indication:
Hepatocellular carcinoma (HCC)
Last updated July 11, 2024
Status:
Negotiations were not pursued
Manufacturer:
LEO Pharma Inc.
Indication:
Atopic dermatitis
Last updated July 2, 2024
Status:
Concluded with an LOI
Manufacturer:
Bayer Inc.
Indication:
Symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilized after a recent heart failure decompensation event requiring hospitalization and/or intravenous diuretic therapy
Last updated June 28, 2024
Status:
Concluded with an LOI
Manufacturer:
Servier Canada Inc.
Indication:
Acute Lymphoblastic Leukemia (ALL)
Last updated June 21, 2024
Status:
Concluded with an LOI
Manufacturer:
Biocon Biologics Canada Inc.
Indication:
Multiple Indications
Last updated June 20, 2024
Status:
Concluded with an LOI
Manufacturer:
Celltrion Healthcare Canada Ltd.
Indication:
Multiple Indications
Last updated June 20, 2024